Table 3

Univariate analyses (logrank test)

n

10-yr. OS (%)

%95 CI (%)

p-value

10-yr. DFS (%)

%95 CI (%)

p-value

10-yr. LC (%)

%95 CI (%)

p-value

10-yr. MM (%)

%95 CI (%)

p-value


All patients

206

52

43–61

25

15–35

79

69–89

72

62–82

Age (year)

≤ 60

103

63

50–76

<0.0001

29

16–42

0.02

79

64–94

0.46

67

53–81

0.007

>60

03

34

19–49

22

9–35

79

67–91

76

62–90

Gender

Female

73

52

36–68

0.98

38

23–53

0.79

88

79–97

0.60

58

43–73

0.77

Male

133

49

37–61

23

13–33

75

62–88

74

63–85

Site of plasmacytoma

Vertebra

102

52

38–66

0.99

19

4–34

0.89

89

79–98

0.07

79

64–94

0.39

Other

104

48

35–61

28

16–40

78

68–88

66

53–79

Largest tumor dimension (cm)

<5

45

67

36–98

0.001

24

7–41

0.73

87

75–99

0.47

79

58–100

0.31

≥ 5

59

57

42–72

34

19–49

78

65–91

58

42–74

NA

102

33

19–47

16

0–33

73

50–96

80

64–96

IgM subtype

Kappa

59

49

19–47

0.57

0

-

0.57

60

24–94

0.49

91

75–100

0.36

Lambda 100

31

61

40–81

35

16–54

87

69–100

65

46–84

NA

116

49

37–61

22

20–44

84

75–93

64

52–76

Type of treatment

RT alone

169

51

40–62

0.49

27

16–38

0.92

78

66–90

0.27

71

60–82

0.93

CT + RT 100

32

43

20–66

15

0–39

93

84-

77

54–100

2 Gy/fr equivalent RT dose (Gy)a

≥ 50

56

47

28–66

0.50

26

10–42

0.06

82

68–96

<0.0001b

71

55–87

0.25

≥ 40 and <50

65

55

34–76

25

6–44

67

40–94

78

59–97

≥ 30 and <40

55

46

28–64

32

16–48

90

81–99

63

47–79

<30

25

37

13–61

17

0–43

96

88–100

81

53–100

No RTc

5

0

-

0

-

0

-

33

0–86


OS: overall survival; CI: confidence interval; DFS: disease-free survival; LC: local control; MM: progression to multiple myeloma; NA: not available; CT: chemotherapy; RT: radiation therapy abiologically effective dose (BED) according to the linear-quadratic model.13 BED = nd(1+ [d÷α/β]) where n = number of fractions, d = dose per fraction, and α/β = 10 for plasmacytoma. bnot significant when excluding patients not receiving radiation therapy. cAll patients treated with surgery alone (with chemotherapy in one).

Knobel et al. BMC Cancer 2006 6:118   doi:10.1186/1471-2407-6-118

Open Data